Previous 10 | Next 10 |
Compugen ( NASDAQ: CGEN ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.14 (-100.0% Y/Y) Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. For furth...
Compugen to Participate in the Stifel Healthcare Conference PR Newswire HOLON, ISRAEL , Nov. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced...
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients PR Newswire Anti-tumor activity following blockade of PVRIG with COM701 when added to nivolumab is supported by potent tumor microenvironment (TME) immune activation in MSS-CRC patients...
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients PR Newswire COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patien...
Compugen Announces Receipt of Nasdaq Delisting Notice PR Newswire HOLON, Israel , Nov. 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced ...
Compugen (NASDAQ: CGEN) , a clinical-stage cancer immunotherapy company, saw its shares rise 9.27% on Tuesday. The stock closed at $0.9518 on Monday and then opened on Tuesday at $0.96. The stock rose to as high as $1.11 a share in the early afternoon before falling to $1.04 at the ...
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022 PR Newswire HOLON, Israel , Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target dis...
Compugen to Present New Clinical Data at ESMO-IO PR Newswire Clinical data from COM701/nivolumab ± BMS-986207 combination studies in patients with platinum resistant ovarian cancer Clinical data from COM701±nivolumab study in patients with metastatic...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 PR Newswire Clinical data from dual combination COM701/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints ...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...